Narendra Modi likely to hold virtual meet tomorrow with states over COVID situation, vaccine distribution plan
The leaders who would attend the meeting include Delhi chief minister Arvind Kejriwal and West Bengal chief minister Mamata Banerjee, sources said
New Delhi: Prime Minister Narendra Modi is likely to meet with chief ministers and other representatives of states and Union Territories via video conferencing on Tuesday to review the COVID-19 situation and discuss the vaccine distribution strategy, sources said.
The leaders who would attend the meeting include Delhi chief minister Arvind Kejriwal and West Bengal chief Minister Mamata Banerjee, sources said.
The prime minister, till now, has held several virtual meetings with states over the coronavirus situation.
While the national daily COVID-19 case count has remained below 50,000 for some time, several urban centres have witnessed a surge, resulting in enforcement of several measures, including curfews in some cities.
The central government has also been putting in place measures for quick and effective distribution of coronavirus vaccine when it becomes available.
Five vaccine candidates are in advanced stages of development in India, out of which four are in Phase II/III and one is in Phase-I/II trials.
India's COVID-19 caseload went past 91,39,865 with 44,059 coronavirus infections being reported in a day, while the recoveries surged to 85,62,641, according to the Union Health Ministry data on Monday.
Second dry run for COVID-19 vaccination drive held in over 700 districts; Delhi govt issues SOPs for UK returnees
The number of people who have tested positive for the new UK variant of SARS-CoV-2 has climbed to 82 in India, the Centre said; the number of such people stood at 73 till 6 January
PM Modi said that while Makar Sankranti ‘reaffirms the importance of respecting mother nature’, Pongal showcases the best of Tamil culture
India inoculates over 12.7 lakh people despite vaccine hesitancy; free jabs reach Seychelles, Myanmar
In a separate but related development, a study published in Lancet found Bharat Biotech's Covaxin showing enhanced immune response without any serious side effects in phase 1 testing